Background: The identification of non-tuberculosis (TB) mycobacterial (NTM) infection remains a significant challenge. This study aims to investigate the diagnostic value of multicolour nested ...
Microbiological confirmation of childhood tuberculosis is rare because of the difficulty of collection of specimens, low sensitivity of smear microscopy, and poor access to culture. A new study aimed ...
During the period from September 2011 to March 2013, a total of 30 TB REACH grants across 24 countries designated funds to procure GeneXpert machines and the Xpert MTB/RIF assay. Of these, a ...
The development of the Xpert MTB/RIF assay has been the most important breakthrough for the diagnosis of tuberculosis in decades. David L. Cohn This molecular-based test provides a rapid and sensitive ...
Evaluation of the Xpert MTB/RIF Test for the Diagnosis of Childhood Pulmonary Tuberculosis in Uganda
In the policy statement on the Xpert MTB/RIF test in 2011, the WHO recommended the use of the test as an initial diagnostic tool among children with suspected HIV associated TB or MDR TB based on ...
FDA Expands Xpert MTB/RIF Test Use The Food and Drug Administration (FDA) has granted clearance for the Cepheid Xpert MTB/RIF Assay to help determine if patients with suspected tuberculosis (TB) can ...
Tuberculosis (TB) causes more deaths globally than any other infectious disease and is a top 10 cause of death worldwide. Globally in 2017, of the estimated 10 million people with TB, 3.6 million were ...
Cepheid, a leading molecular diagnostics company, and FIND, an international non-profit organisation, launched the GeneXpert Omni, the world's most portable molecular diagnostics system enabling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback